Posted on

IT Pharma opens its first beauty centre in Portugal

IT Pharma opens its first beauty centre in Portugal

Daniela Stoica, the distributor for IT Pharma Portugal, is to manage the first centre in Lisbon for treatments and training services

The range of services offered by the centre will include treatments directed at the end customer, as well as training workshops and courses for professionals in the sector, conferences with experts in different fields and demonstrations and the sale of products from the company’s different lines.

According to its manager, the goal is to “offer a range of treatments that are particularly focussed on advanced aesthetics, with top quality products and proven safety.” The treatment range available at the beauty centre will include facials and body care, all using product lines, services and technology that are exclusive to IT Pharma.

In the words of Daniela, “the goal of this first beauty centre is to offer customers excellent service, ongoing training for professionals in the sector and to make it possible to expand the company’s product lines throughout the country. We’re really excited about this new step forward”.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

Make a comment

Posted on

“Biopeptides are going to be the key ingredients in the cosmetic medicine treatments of the future”

“Biopeptides are going to be the key ingredients in the cosmetic medicine treatments of the future”

Dr Yong Ji Chung, president of the biotechnology multinational Caregen, gave a paper on ‘Biopeptides in cosmetic medicine and their future in the sector’ at a conference organised by IT Pharma.

The conference on cosmetic medicine, organised by IT Pharma, was held on Saturday 1 September in Hotel Hiberus in Zaragoza.

Last weekend, Dr Chung, president and founder of the Korean multinational Caregen Co., which produces and distributes cosmetic medical products, gave a paper on ‘Biopeptides in cosmetic medicine and their future in the sector’ at Hotel Hiberus in Zaragoza.

In it he pointed out that ‘a great many ingredients have been used for cosmetic medicine in the past, but modern-day biopeptides are much more powerful and effective for a multitude of cases and patients.’ While the Korean company is involved in ongoing research into these amino acid chains, its president stressed that ‘Caregen has managed to develop more than 450 biopeptides, which will generate numerous applications in the future. Many active ingredients have been used in the aesthetic market over time, but peptides are much more powerful in comparison. That is because they act just like our own growth factors and cytokines, and this makes them much more effective. So, in view of the current conditions of the aesthetic market, peptides are going to be the key ingredients in treatments in the future“.

The event organised by IT Pharma in collaboration with TOV Medical also included a round table afterwards with the participation of Dr Chung, Dr Juan Miguel Pérez Díaz from Madrid’s Clínica Pérez Díaz, Dr Rafael Spagnuolo from Clínica Spagnuolo in Marbella and Dr Inma González, the founder of CISIG. The participants shared their experiences with current cosmetic medical cases, the types of treatment most demanded by patients nowadays, the challenges facing the sector and new trends on their way in.

PICTURES ON FACEBOOK

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

Make a comment

Posted on

Caregen celebrates its first Global Partner Meeting

Caregen celebrates its first Global Partner Meeting

The first meeting of Caregen distributor companies and collaborators, attended by Dr Chung – CEO of the Korean company – brought over 20 companies from around the world together in Seoul.

Over 20 companies came together for the first international distributors and collaborators meeting organised by Caregen in Seoul, Korea.

The first meeting of Caregen distributor companies and collaborators, attended by Dr Chung – CEO of the Korean company – brought over 20 companies from around the world together in Seoul. Sergio García and Carmelo López, partners of IT Pharma, attended the meeting in representation of the Navarran brand, to exchange experiences, impressions, and the latest news and strategies for 2019.

During the event, and as the main new change, attendees were informed that the new product from the Prostrolane line (which treats eye bags), Inner B SE, has been given the EC certification, meaning it can be sold in Spain in the near future.

The meeting ended with a gala dinner that took place at the Hotel Hyatt in Seoul.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

Make a comment

Posted on

Genera Pharma. New partnership between IT Pharma and Laboratorios VICU

Genera Pharma. New partnership between IT Pharma and Laboratorios VICU

La Joint Venture with IT Pharma will now have a new white room in the Zaragoza-based facilities
A new partnership between IT Pharma and Laboratorios VICU

The Innovation, Research and University Adviser, Pilar Alegría, has opened the new manufacturing white room of Laboratorios Vicu – the IT Pharma group’s partner-company – located in Magnus Park in the Empresarium Industrial Estate.

The aim of the Genera Pharma – the new strategic alliance between the IT Pharma group and the Laboratorios Vicu of Zaragoza – is to develop, manufacture and market food supplements, cosmetics, healthcare products, pharmaceutical active ingredients and semi-finished biotechnological products, as well as to manufacture for third parties.

Pilar Alegría outlined that it is a company with a strong technological base within the highly competitive sector of biotechnology.

Carmelo López, CEO of IT Pharma, stated that “for us this is a step further down the line towards internationalising our products and more rigorous manufacturing control, all with a company that will help us develop our projects in the short, medium and long term”.

The founding partner and CEO of Laboratorios Vicu, Iván Galindo, reinforced that: “Our shared Joint Venture, GENERA PHARMA, will act as a spearhead for many different markets, with three own product lines with identifiable names and brands. I am sincerely very proud to have joined this great Navarran group on the road to this venture, with which we can work together and continue to grow”

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

Make a comment